Compare MEG & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | XERS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 1.0B |
| IPO Year | 2020 | 2021 |
| Metric | MEG | XERS |
|---|---|---|
| Price | $22.14 | $6.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $35.25 | $10.83 |
| AVG Volume (30 Days) | 238.0K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 93.69 | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $830,538,000.00 | $49,590,000.00 |
| Revenue This Year | $5.41 | $34.37 |
| Revenue Next Year | $7.19 | $22.86 |
| P/E Ratio | ★ N/A | $642.00 |
| Revenue Growth | 19.26 | ★ 142.67 |
| 52 Week Low | $19.00 | $4.30 |
| 52 Week High | $32.00 | $10.08 |
| Indicator | MEG | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 50.24 |
| Support Level | $20.80 | $5.79 |
| Resistance Level | $23.48 | $6.41 |
| Average True Range (ATR) | 0.79 | 0.27 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 88.92 | 28.07 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.